Predicting treatment success with PET scans in prostate cancer
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study looks at whether a special PET scan can help predict how well a targeted radiation therapy (LuPSMA) works in men with advanced prostate cancer that has spread. You would get several PET scans before and after treatment to see if the scan results can forecast your outcome.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of advanced prostate cancer that has spread and is no longer responding to hormone therapy.
- You are scheduled to receive a treatment called LuPSMA (a radiation therapy that targets prostate cancer cells).
- You are willing to have multiple PET scans before and after your LuPSMA treatment.
- You are able to understand and sign a consent form.
- You are 18 years or older.
- You do not have any medical condition that would make it unsafe or hard for you to participate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a special PET scan (fluciclovine) to see if it can better detect prostate cancer that has low PSMA levels or has changed to a neuroendocrine type. It may help find tumors that standard PSMA scans miss.
This study tests whether a newer type of imaging scan (called fluciclovine PET) can find where prostate cancer has come back when an earlier scan (PSMA PET) didn't show clear results. The goal is to help doctors better plan treatment for men whose cancer has returned after surgery or radiation.
This trial tests a new PET scan (a type of imaging) called Flotufolastat to see if it can better monitor prostate cancer after you receive focal therapy—a treatment that targets only the cancer area rather than the whole prostate. The goal is to help doctors know if the treatment worked and catch any remaining cancer early.
This trial uses a special PET scan (POSLUMA) before and after radiation to see if it helps treat prostate cancer that has spread to a few spots outside the pelvis. It's for men whose cancer still responds to hormone therapy and who have not had widespread spread.
This study uses a special PET/CT scan (Flotufolastat F 18) to look for leftover or returning prostate cancer after you've had a targeted treatment called focal therapy. The goal is to see if the scan can help find cancer that might need further treatment.
This trial tests whether a special PET scan can predict how well a targeted radiation therapy (177Lu-PSMA-617) works for men with advanced prostate cancer that has stopped responding to hormone therapy. It aims to personalize treatment by checking the radiation dose before therapy starts.
Hear when a new Prostatic Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.